Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $15

Benzinga | Dec 15, 2021 8:56 AM EST

Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $15

Morgan Stanley maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $20 to $15.